| Applications: | Immunodepletion/Immunocompetition |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description : | AGE Blocking Peptide for STJ500054 is synthetically produced from the sequence and is suitable for use in western blot applications. |
| Formulation: | Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: | Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Specificity: | This blocking peptide is recommended for use in combination with AGE antibody, STJ500054 |
| Immunogen: | Purified glycated ribonuclease corresponding to AGE. Glycated ribonuclease (RNase) prepared by incubating RNase with glucose at 37⁰C for several months. |
| Background | Mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. |
Information sourced from Uniprot.org